reports
Enzon and Viskase Enter into Merger Agreement
Enzon and Viskase Enter into Merger Agreement Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company CRANFORD, N.J. and LOMBARD, Ill., June 20, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQX: ENZN) (“Enzon” or the “Company”) and Viskase Companies, Inc. (OTC Pink Limited: VKSC) (“Viskase”) announced that they have entered into a definitive merger agreement (the “Merger Agreement”), pursuant to which Viskase will merge with and into a wholly owned subsidiary of Enzon in an all-stock transaction (the “Merger”). Following the ...
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. F...
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO CRANFORD, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTC:ENZN) announced today that Andrew Rackear has communicated to the Board his intent to retire from his role as the Company’s Chief Executive Officer effective February 26, 2021. Andy joined Enzon in 2010 as Vice-President and General Counsel and has served as CEO since 2016. Upon Andy’s retirement, Richard L. Feinstein, Enzon’s Chief Financial Officer, will also assume the rol...
Enzon Pharmaceuticals Announces Results of Rights Offering
Enzon Pharmaceuticals Announces Results of Rights Offering Looking to Next Step – Acquisition Opportunities CRANFORD, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) announced the results of its rights offering following the expiration of the subscription period on October 9, 2020 at 5:00 p.m. New York City Time. Under the rights offering, 40,000 units were available for purchase and holders of Enzon’s common stock received one transferable subscription right for each share of common stock owned. For every 1,105 subscription ri...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meet...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 2020 annual meeting of stockholders (the “Annual Meeting”) originally scheduled to be held on Thursday, September 17, 2020, has been postponed and will now be held on Friday, December 18, 2020. Once determined by the Company’s Board of Directors, the Company will announce the record date, time and location of the 2020 Annual Meeting. The Company decided to postpone the 2020 A...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Sharehol...
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders CRANFORD, N.J., Aug. 21, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC: ENZN) today announced that its Board of Directors (the “Board”) has approved a rights offering to existing shareholders whereby the Company intends to distribute one transferable subscription right for each outstanding share of common stock owned. For every 1,105 subscription rights held, a shareholder will be entitled to purchase one unit. The Company plans to offer 40,000 units, at a subscription price ...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to P...
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value CRANFORD, N.J., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its Board of Directors (the “Board”) adopted a tax benefits preservation plan (the “Section 382 Rights Plan”) designed to protect the availability of Enzon’s net operating loss carryforwards (“NOLs”) under the Internal Revenue Code (the “Code”). As of December 31, 2019, Enzon had U.S. federal and state NOLs and tax credits, including approxi...
- GlobalData Department
Enzon Pharmaceuticals Inc (ENZN) - Pharmaceuticals & Healthcare - Deal...
Summary Enzon Pharmaceuticals Inc (Enzon), formerly Enzon, Inc., is a pharmaceutical company that receives royalty revenues from existing licensing arrangements. The company has licensing arrangements with other companies related to sales of their four marketed drug products, namely, PegIntron, Sylatron, Macugen and CIMZIA. Enzon sources its royalty revenues primarily through the sale of PegIntron, which is marketed by Merck & Co., Inc. PegIntron received an approval from European Union, the US...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.